Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.

A higher occurrence of MSEs was observed in the comparator group, which was marginally significant (p=0·05).

also in 26,082 other papers

In the Vi-DT group, 11·4% (16·1% in Group A and 6·5% in Group B) had solicited AEs while 9·1% in the comparator group had AEs; the differences did not reach statistical significance, neither were they considered as clinically significant differences.

also in 111,027 other papers